KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.96

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.

Roy S Herbst, Thomas John, Christian Grohé, Jonathan W Goldman, Terufumi Kato, Konstantin Laktionov, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine, Myung-Ju Ahn, Dariusz M Kowalski, Maurice Pérol, Virote Sriuranpong, Mustafa Özgüroğlu, Preetida Bhetariya, Aleksandra Markovets, Yuri Rukazenkov, Caitlin Muldoon, Jacqulyne Robichaux, Ryan Hartmaier, Masahiro Tsuboi, Yi-Long Wu

Nat Med 31(6) 1958-1968

PMID40097663
PMCIDPMC12176615
DOI10.1038/s41591-025-03577-y
发表日期2025-03-18
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:森林图/亚组分析图;Fig. 5:森林图/亚组分析图;另有 2 张未列出。
摘要

摘要

Osimertinib-a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor-is recommended as adjuvant therapy for resected stage IB-IIIA epidermal growth factor receptor-mutated non-small-cell lung cancer, based on significant disease-free survival (DFS) and overall survival improvement shown in the previously reported phase 3 ADAURA trial. A trend toward an increased DFS event rate after completion of 3 years adjuvant treatment in ADAURA suggests that some patients may benefit from longer adjuvant osimertinib treatment. We therefore explored whether tumor-informed, circulating tumor DNA-based, molecular residual disease (MRD) could predict recurrence in an exploratory post hoc analysis of 220 patients (n = 112 osimertinib; n = 108 placebo) from ADAURA. MRD preceded imaging DFS events in this study by a median of 4.7 (95% confidence interval, 2.2-5.6) months. DFS and MRD event-free rate at 36 months was 86% versus 36% for patients in the osimertinib versus placebo groups (hazard ratio, 0.23 (95% confidence interval, 0.15-0.36)). In the osimertinib group, DFS or MRD events were detected in 28 (25%) patients; most events occurred following osimertinib cessation (19 of 28, 68%) and within 12 months of stopping osimertinib (11 of 19, 58%). At 24 months after osimertinib, the DFS and MRD event-free rate was 66%. In this study, MRD preceded DFS events in most patients across both arms. DFS and MRD event-free status was maintained for most patients during adjuvant osimertinib treatment and posttreatment follow-up, with most MRD or DFS events occurring after osimertinib treatment discontinuation or completion. MRD detection could potentially identify patients who may benefit from longer adjuvant osimertinib, although this requires clinical confirmation. ClinicalTrials.gov identifier: NCT02511106 .

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Study population and MRD analysis. a , ADAURA study design and sample collection schedules. b , Patient disposition for the MRD analysis set. a At the time of recruitment, staging was determined by the AJCC Staging Manual 7th ed. b Preoperative, postoperative or planned radiotherapy was not allowed. c EGFR mutation status was centrally confirmed in tissue. d Patients received a CT scan after resection and within 28 days before treatment. e Patients were stratified by stage (AJCC 7th ed. 42 , IB versus II versus IIIA), EGFR mutational status (Ex19del versus L858R) and race (Asian versus non-Asian). Patients with stage IB disease were not eligible in Japan. f Collected until disease recurrence or study end. g Of 682 patients randomized in ADAURA, 239 had matched tumor, plasma and germline DNA samples and were eligible for MRD analyses; ctDNA was not collected in China and some patients declined the optional germline sample. h DCO for MRD analysis was 25 March 2024. C1D1, cycle 1 day 1; QC, quality control; WHO, World Health Organization.
非 KM Figure
Fig. 2Clearance of baseline MRD. a , MRD events occurring at randomization in the MRD analysis set. b , MRD status at randomization by disease stage (stage IB, II and IIIA) and receipt of previous adjuvant chemotherapy in the MRD analysis set. c , Longitudinal analysis of MRD status (undetected or detected) and DFS outcomes (local and/or regional, distant and death) for patients with detected MRD at randomization across both the osimertinib and placebo groups. d , Percentage variant allele frequency (VAF) detected in plasma samples over time among patients in the osimertinib ( n = 5) and placebo ( n = 13) groups with detected MRD at randomization. e , Proportion of patients in the osimertinib and placebo groups showing clearance of MRD detected at randomization. a CNS-only DFS event. b Patients received placebo for up to 36 months. Chemo, chemotherapy; VAF, variant allele frequency.
非 KM Figure
Fig. 3Longitudinal MRD analysis of plasma samples from patients in the MRD analysis set. Swimmer plots for the osimertinib and placebo groups showing the MRD status (undetected, detected or not tested) and clinical status (DFS event) of patients in the MRD analysis set over time (randomization, treatment and posttreatment follow-up periods). a Patients received placebo for up to 36 months.
非 KM Figure
Fig. 4Effect of osimertinib on molecular and disease recurrence. a , Lead-time analysis of the median time from MRD detection to a DFS event performed for the 62 patients across both treatment groups with both a postrandomization DFS event and any plasma sample with detected MRD. Each point on the plot represents a single patient. The center vertical line represents the median time from MRD detection to a DFS event. The whiskers represent the minimum and maximum time from MRD detection to a DFS event and the box limits are representative of upper and lower quartiles. In this study, MRD preceded a DFS event by a median of 4.7 (95% CI, 2.2–5.6) months. b , Kaplan–Meier analysis in the MRD analysis set of the time from randomization to the combined endpoint of DFS (clinical recurrence or death) or MRD events assessed postrandomization (whichever event occurred first) in the osimertinib and placebo groups. The DFS and MRD event-free rate is shown for landmark analyses at 24 and 36 months. HRs and 95% CIs were calculated using an unadjusted Cox proportional hazards model. c , DFS or MRD events occurring in the osimertinib versus placebo group. For the osimertinib group, DFS or MRD events occurring on treatment and after treatment discontinuation or completion are shown. Percentages were calculated by dividing the total number of MRD or DFS events by the total number of patients in each subgroup.
非 KM Figure
Fig. 5Genomic analysis of WES data from baseline tumor samples of patients in the MRD analysis set. a , OncoPrint for patients in the MRD analysis set showing oncogenic driver alterations (occurring in >1% of samples), MRD and DFS events, MRD status at randomization, adjuvant chemotherapy status and disease stage. b , Proportion of patients with TP53 alterations by disease stage and receipt of previous adjuvant chemotherapy. c , Analysis of DFS and MRD event-free survival for osimertinib versus placebo for disease stage, receipt of previous adjuvant chemotherapy and TP53 mutation status. The number of patients varied in each subgroup as reported on the graph. The subgroup analyses were performed using a Cox proportional hazards model including treatment, subgroup and treatment by subgroup interaction. HR (blue dots) and 95% CI (horizontal lines) are shown for each subgroup. An HR of <1 favors osimertinib. Adj, adjuvant; amp, amplification; osi, osimertinib; pbo, placebo; WT, wild type.
非 KM Figure
Extended Data Fig. 1Comparison of EGFR mutation (Ex19del and L858R) and MRD assay performance. a , Flow chart showing samples included as part of the EGFR mutation analysis. b , Lead-time analysis demonstrating median time from EGFR mutation detection to MRD detection, EGFR mutation detection to a DFS event, and MRD detection to a DFS event performed for the 40 patients across both groups with a post-randomization DFS event, any sample with detected MRD, and any sample with detected EGFR mutation. EGFR mutation preceded detected MRD by a median of 0.0 (95% CI −2.9–0.0) months, EGFR mutation preceded a DFS event by a median of 1.0 (95% CI 0.0–5.2) month and MRD preceded a DFS event by a median of 4.6 (95% CI 1.8–5.6) months. Each point on the plot (triangle/square/circles) represents a single patient. The whiskers represent the minimum and maximum lead time between events and the box limits are representative of the 95% CI.
非 KM Figure
Extended Data Fig. 2Multivariable analysis adjusting for disease stage, adjuvant chemotherapy status and TP53 mutation type on the DFS or MRD combined endpoint fitted separately for each group. The number of patients varied in each subgroup as reported on the graph. HRs and 95% CIs were calculated using the Cox proportional hazards model. The HRs (represented by black dots) and 95% CIs (horizontal lines) are shown for each subgroup.
非 KM Figure